ClinicalTrials.Veeva

Menu
The trial is taking place at:
C

Canberra Hospital | Gastroenterology Department

Veeva-enabled site

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Incyte logo

Incyte

Status and phase

Active, not recruiting
Phase 3

Conditions

Renal Cell Carcinoma (RCC)

Treatments

Drug: Pazopanib
Drug: Epacadostat
Drug: Sunitinib
Drug: Pembrolizumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT03260894
2017-002259-26 (EudraCT Number)
KEYNOTE-679/ECHO-302

Details and patient eligibility

About

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.

Enrollment

129 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologic confirmation of locally advanced or metastatic RCC with a clear-cell component with or without sarcomatoid features.
  • Must not have received any prior systemic therapy for their mRCC.
  • Measurable disease based on RECIST v1.1.
  • Archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion as required.
  • Karnofsky performance status ≥ 70%.
  • Adequate organ function per protocol-defined criteria.

Exclusion criteria

  • Use of protocol-defined prior/concomitant therapy.
  • Currently receiving or has received an investigational treatment as part of a study of an investigational agent or has used an investigational device within 4 weeks before randomization.
  • History of severe hypersensitivity reaction to study treatments or their excipients.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Known additional malignancy that has progressed or has required active treatment in the last 3 years.
  • Known active central nervous system metastases and/or carcinomatous meningitis.
  • History of (noninfectious) pneumonitis that required steroids or current pneumonitis.
  • History or presence of an abnormal electrocardiogram that, in the investigator's opinion, is clinically meaningful.
  • Significant cardiac event within 12 months before Cycle 1 Day 1.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

129 participants in 2 patient groups

Pembrolizumab + Epacadostat
Experimental group
Treatment:
Drug: Pembrolizumab
Drug: Epacadostat
SoC (Sunitinib or Pazopanib)
Active Comparator group
Description:
Standard of care (SoC) (sunitinib or pazopanib monotherapy).
Treatment:
Drug: Sunitinib
Drug: Pazopanib

Trial documents
1

Trial contacts and locations

140

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems